**Advances in understanding cellular mechanisms of cardiovascular complications and retinopathy in diabetes: Therapeutic potential of phytochemicals**

**Tamsheel Fatima Roohi1, Syed Faizan2, K L Krishna1, Seema Mehdi1**

**1Tamsheel Fatima Roohi**

Ph.D. Research Scholar

Department of Pharmacology,

JSS College of Pharmacy,

JSS Academy of Higher Education & Research,

Mysuru -570015, Karnataka India

E-mail: tamsheelfatimaroohi22@gmail.com

Orcid Id: 0000-0002-8785-269X

Mobile: +91 73762 88410

**1Dr. K. L. Krishna**

Associate Professor and HOD

Department of Pharmacology

JSS College of Pharmacy

JSS Academy of Higher Education & Research

Mysore - 570 015 Karnataka, India

E-mail: klkrishna@jssuni.edu.in,

Orcid Id: [0000-0001-7538-0798](https://orcid.org/0000-0001-7538-0798)

Mobile: +91 9886610010

**2Syed Faizan**

Ph.D. Research Scholar

Department of Pharmaceutical Chemistry,

JSS College of Pharmacy,

JSS Academy of Higher Education & Research,

Mysuru -570015, Karnataka India

E-mail: sfaizan313@gmail.com

Orcid Id: 0000-0001-6104-0557

Mobile: +91 7204618011

**1Dr. Seema Mehdi**

Lecturer

Department of Pharmacology,

JSS College of Pharmacy,

JSS Academy of Higher Education & Research,

Mysuru -570015, Karnataka India

E-mail: seemamehdi@jssuni.edu.in

Orcid Id: 0000-0002-3212-0774

Mobile: +91 9739693766

**ABSTRACT**

Comprehensive knowledge of the pathophysiology, aetiology, and clinical course of diabetes mellitus is paramount to prognosticating cardiovascular and ocular complications. This chapter investigates the mechanisms and processes governing the progressive development of cardiovascular complications and retinopathy in patients with diabetes. We also aimed to determine the diabetes prevention and management potential of multimodal treatments (including phytochemical methods). Thirty-four research articles were analysed to determine the pathophysiology, cellular mechanisms, and biomarkers associated with cardiovascular and ocular complications of diabetes. Data sources included PubMed Central, Web of Science, and JSTOR. Data extraction was guided by the advanced filters of the respective databases. Primary and secondary research articles with the latest evidence on the pathobiology and treatment of diabetic complications were extracted for this updated review. The predominant causes of diabetic retinopathy and diabetic macular edema include haemorrhage and retinal capillary aneurysms. Diabetes type, age at diagnosis, and race are independent predictors of the risk and incidence of non-proliferative and proliferative diabetic retinopathy (NPDR/PDR). In addition, 75% of diabetes-related deaths are attributed to cardiovascular complications including peripheral vascular disease, thromboembolism, stroke, nephropathy, coronary artery disease, and atherosclerosis. Training researchers and physicians on the therapeutic efficacy of phytochemical methods against NPDR/PDR and diabetes-related cardiovascular diseases is needed to increase their use in adjuvant treatments. In addition, comprehensive knowledge of the pathophysiology/cellular mechanisms of diabetes is paramount for improving treatment outcomes. Future studies should investigate the medicinal value of various plant extracts, including their phytochemicals, to transform the therapeutic landscape for diabetes management.

**Keywords-** Diabetes; NPDR; PDR; retinopathies; cardiovascular; phytochemicals; Rutin; Quercetin; Hesperidin

1. **INTRODUCTION**

Patients with diabetes remain predisposed to life-threatening complications including cardiac arrest, coronary artery disease, myocardial infarction, and stroke (1) (**Figure 1**). Currently, 4.2 million or 28.5% of individuals with diabetes (age ≥40 years) experience retinopathy; possibly, this complication will affect 93 million or 34.6% of people worldwide by 2050. Notably, 80% of patients with a history of diabetes > 20 years develop retinopathy (2). Evidence reveals the possibility of preventing a >90% incidence of diabetic retinopathy with proper monitoring and treatment of ocular disease (3). Several studies indicate that a long-term history of diabetes increases the risk and incidence of diabetic retinopathy (4). At least 12% of patients with diabetic retinopathy develop blindness annually in the United States, and retinopathy in diabetes is the primary contributor to blindness in patients age 20-64 years (5). Retinal degeneration-related microvascular breakdown is the primary outcome of diabetic ischemic maculopathy. Affected patients are at high risk of developing central vision loss (6,7). Diabetic retinopathy is classified by neovascularization in interconnected vascular lesions and is categorized into proliferative and non-proliferative subtypes (8). Ocular inflammation and edema are the outcomes of liquefied collections in the retinal fovea or macula lutea (9). The findings of the Diabetes Control and Complications Trial (DCCT) indicate improved treatment outcomes in patients with diabetes who received critical care and achieved glycemic control via metabolic memory phenomenon or legacy effect (10-12). Clinical studies have revealed the incidence of pericyte disintegration and mortality based on the disintegration of endothelial cells due to advanced glycation end products (AGEs), oxidative stress, and hyperglycemia (13). Patients with diabetic retinopathy usually do not develop reportable symptoms during the initial stages; however, progressive disease (in its advanced stages) triggers ocular complications. Diabetic retinopathy affects vascular supply in both eyes and induces retinal vasculitis. This further leads to retinal microaneurysms, macular edema, and inflammation. Complications include bilateral complete vision loss, appearance of eye floaters or black spots (hindering vision), poor night vision, drusen or white spots on the retina, color vision deficiency/color blindness, and eyesight issues (14).



**Figure 1:** **Bibliometric analysis of keywords in publications on diabetes and its complications**. Co-occurrence of keywords. The size of the nodes indicates their frequency of occurrence. The curves between the nodes represent their co-occurrence in the same publication. The shorter the distance between two nodes, the larger is the number of co-occurrences of the two keywords. Keywords such as “Diabetic Retinopathy,” “cardiovascular disease,” “T1DM,” “T2DM,” “Insulin resistance” and “Biomarkers” occurred most common. *Source: VOS viewer.*

1. **PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY**

High oxidative stress in the retina is the outcome of glucose oxidation, maximum oxygen uptake, and accumulation of polyunsaturated fatty acids, which eventually induce reactive oxygen species (ROS), thereby altering the expression of vascular endothelial growth factor (VEGF) (15,16). Retinopathy is the outcome of prostaglandin E2 and cyclooxygenase-2 (COX-2) activation, and the induction of inflammatory mediators by oxidative stress. Other pathophysiological processes involved in the development of diabetic retinopathy include renin-angiotensin system (RAS) stimulation, activation of protein kinase C, and accumulation of AGEs (17,18). Diabetic retinopathy further develops due to hyperglycemia-induced metabolic stress, leading to vascular damage and neuralgia. Leaking and fragile blood vessels replace damaged vessels following the noticeable degeneration of retinal endothelial cells (19,20). The nonreceptor protein tyrosine kinase (Src) is regulated upstream by pericyte-induced angiopoietin 1, which interacts with the TIE2 endothelial cell receptor. The induction of angiopoietin 1 and TIE 2 activates platelet-derived growth factor and transforming growth factor signaling in endothelial cells (21). In addition, the proinflammatory cytokines interleukin (IL)-17A, IL-6, tumour necrosis factor (TNF), and monocyte chemoattractant protein (MCP)-1are potential markers of diabetic retinopathy based on their attribution to endothelial cell death and vascular leakage (22,23).

1. **BIOCHEMICAL AND CELLULAR PATHWAYS RESPONSIBLE FOR DIABETIC RETINOPATHY**

To date, the current literature does not elaborate on viable mechanisms and pathways with their attributions to retinal deterioration in diabetes, which is predominantly the outcome of poor glycemic control. Diabetic retinopathy involves a range of complex mechanisms induced by the hexosamine pathway, oxidative stress, polyol pathway, inflammatory mediators, AGEs, and protein kinase C. Diabetic retinopathy progresses with mitochondrial dysfunction and ROS activation induced by nicotinamide adenine dinucleotide phosphate (NADPH) stimulation. The vicious cycle of ROS induction is prolonged by the continuous damage to mitochondrial cells under the influence of superoxide radicals from the mitochondrial electron transport chain (ETC). Patients with diabetes develop high levels of metabolic disruptions, hormonal imbalances, and hyperglycemia. Inflammatory processes in diabetes are governed by adhesion molecules, elevated capillary density, increased blood flow, neurotrophic factors, inflammatory compounds, vasoactive agents, and chemokines. The early stages of diabetic retinopathy are also associated with angiogenesis, apoptosis, and vascular permeability (24-30).

1. **BIOMARKERS OF DIABETIC RETINOPATHY**

The diagnostic assessment of diabetes relies on findings from the oral glucose tolerance test, fasting blood glucose level test, and glycated hemoglobin (HbA1C) evaluation. Glycemic control must be measured by determining the HbA1C level, which is also a marker of cardiovascular disease in diabetes (31,32). Other diagnostic biomarkers of diabetes include glycated albumin and fructosamine. Recent studies indicate an uncertainty or standard deviation of ± 7.8 mmol/L in determining glycemic control by assessing fructosamine levels. In addition, overall serum lipid and protein levels appeared to confound the outcomes of the fructosamine assessment test. Recent evidence has revealed a high concentration of glycated albumin in patients with poor glycemic control. Compared to postprandial glucose (PPG), fasting plasma glucose (FPG) correlates more with HbA1C levels; however, both have a clinically significant association with fructosamine in type 2 diabetes. Total glycemic control in diabetes is best determined by PPG based on its greater correlation with HbA1C. In addition, a comparison of HbA1C with fructosamine indicated a minimal (+) association with the mean glucose profiles of patients with type 2 diabetes. These results negate the notion of the overall glycemic control prediction capacity of HbA1C in diabetes (33). Overall, the HbA1C level is not a strong clinical indicator of glycemic control. **Table 1** depicts the prognostic indicators and novel biomarkers of diabetic retinopathy, such as AGEs, advanced glycation end-products; CRM, corneal confocal microscopy; DNA, deoxyribonucleic acid; eGFR, estimated glomerular filtration rate; ERG, Electroretinogram; NO nitric oxide; PAI-1, plasminogen activator inhibitor 1; PEDF, pigment epithelium-derived factor; RAGE, receptor for advanced glycation end-products; SAF, Skin autofluorescence; SNPs, single-nucleotide polymorphisms; VEGF, vascular endothelial growth factor.

**Table 1: Prognostic indicators/novel biomarkers of diabetic retinopathy.**

|  |
| --- |
| **Routine and novel biomarkers of diabetic retinopathy** |
| Clinical (general) biomarkers | * Age
* Type of diabetes
* Duration of diabetes
* Family history
* Lifestyle
* Obesity
* High blood pressure
* Pulse wave analysis
* SAF
* AGEs
 |
| Clinical (ocular) biomarkers | * Stage of retinopathy
* Retinal vessel calibre
* CRM
* ERG
 |
| Biochemical biomarkers | * Glycemia (HBA1c level)
* Serum creatinine
* eGFR
* Urine albumin
* Adiponectin
* Lipid and lipoprotein
* Vitamin D
* Homocysteine
* Inflammation molecules
* Cytokines
* Chemokines
* AGEs
* RAGE
* Growth-related factors (VEGF/PEDF)
* Endothelin-1
* NO
* Fibrinogen
* PAI-1
 |
| Molecular biomarkers | * SNPs
* Histone modifications
	+ DNA methylation
	+ Histone deacetylation
	+ Histone acetylation
* Non-coding RNAs/MicroRNAs
* Metabolomics
* Lipidomics
* Glycomics
	+ Study of modified glucose/lipids/proteins
 |

1. **DIAGNOSIS OF DIABETIC RETINOPATHY**

Routine ophthalmic assessments are paramount for diagnosing retinopathy in diabetes; repeat examinations facilitate early diagnosis (i.e., assessment of the condition at the initial stage of the disease). Patients with diabetes require annual or biannual assessments to determine their risk of retinopathy. The diagnostic workup is guided by symptomatology, including signs and clinical manifestations. Differential assessments for advanced eye disease, moderate/severe non-proliferative retinopathy, and maculopathy in diabetes are paramount to improving medical decision-making (34,35). **Table 2** lists the diagnostic parameters for diabetic retinopathy.

**Table 2: Diagnostic parameters for diabetic retinopathy.**

|  |  |
| --- | --- |
| **Type of diabetic retinopathy** | **Diagnostic parameters** |
| Acute non-proliferative diabetic retinopathy | * Microaneurysm
* Hard exudates
* Renal oedema/thickening
* Retinal haemorrhage
 |
| Maculopathy | * Oedema/thickening in the macular retina
 |
| Chronic non-proliferative diabetic retinopathy | * Cotton wool spots
* Vascular abnormalities
* Venous bleeding
* IRMA
 |
| Proliferative diabetic retinopathy | * NVD
* NVD elsewhere
* Vitreous haemorrhage
 |
| Advanced eye disorder | * Vitreous haemorrhage
* Pre-retinal fibrosis
* Retinal detachment
 |

1. **CARDIOVASCULAR COMPLICATIONS**

Cardiovascular disease is an independent predictor of morbidity and mortality in patients with diabetes, and more than 30% of patients with diabetes experience cardiovascular complications worldwide. The predominant cardiovascular complications of diabetes include cardiac dysfunction, stroke, myocardial infarction, and premature atherosclerosis (36,37). Risk factors, including persistent blood pressure elevation, poor glycemic control, and dyslipidemia, predict early onset of cardiovascular disease in diabetes. Disintegration of complex atherosclerotic plaques in the arteriovenous system results in strokes, unstable angina, and myocardial infarction; however, the etiopathology of these episodes has not yet been determined. The binding of T lymphocytes and other macrophages to the walls of arteries leads to localized abnormalities, including atherogenesis (38). Diastolic dysfunction marks the onset of coronary artery disease in asymptomatic patients with myocardial damage. The diagnostic workup relies on echocardiography. In addition, hyperglycemia in diabetes activates the inflammatory, migratory, and proliferative attributes of dormant non-contractile muscle cells (39). These processes eventually lead to the development of a proatherogenic environment, thereby increasing systemic/tissue-specific insulin resistance (**Figure 2**).

****

**Figure 2: Novel biomarkers for diabetes-related retinopathy complications [36-39].**

illustrates the pathogenesis of hyperglycemia (in diabetes) and its association with cardiovascular manifestations. The severity of clinical complications of diabetes is indicated by high blood glucose levels. Asymptomatic patients with prediabetes or type 2 diabetes also experience a high risk of clinical complications including fatty acid mobilization, ketonuria, weight loss, increased appetite, and urinary frequency. Other potential complications of diabetes include vaginal and skin infections, dental abscesses, blurry vision, irritability, fatigue, and non-healing wounds.

1. **CELLULAR AND BIOCHEMICAL MECHANISMS OF CARDIOVASCULAR COMPLICATIONS IN DIABETES**

Cardiovascular complications in diabetes are caused by insulin resistance and hyperglycemia. The onset and progression of diabetes triggers the accumulation of ROS, which eventually disrupts cellular function and homeostatic regulation of the vascular system, leading to cardiovascular pathology (40,41). Preclinical studies in rodents provide inconclusive evidence concerning a possible correlation between complex plaque rupture and the development of coronary atherosclerosis, heart failure, or fibrosis. Current data indicating cardiovascular complications in diabetes do not elaborate the role of end-stage diabetes in the onset and progression of cardiovascular manifestations. The contemporary literature reveals distinct mechanisms governing the pathophysiology of atherosclerosis, fibrous plaques, plaque rupture, and complex lesions in diabetes. However, these findings were mainly derived from cell culture experiments with limited reliability (42-44). The predominant crosstalk mechanisms governing atherosclerosis development in diabetes affect the normal function of the liver, visceral fat, bone marrow, phagocytic cells, smooth muscles, endothelial cells, and inflammatory mediators (45). Several clinical studies have suggested a possible association between cardiovascular disease in diabetes and the polyol/sorbitol pathway. Findings from a preclinical study in apolipoprotein E knockout mice indicated the exacerbation of atherosclerosis due to aldose reductase overexpression (46). The outcomes of a preclinical study revealed comparable atherogenesis and endothelial inflammation in non-diabetic apolipoprotein-deficient and glyoxalase-1 inhibitor-induced diabetic mice (47). In addition, clinical studies have indicated an association between plaque accumulation/rupture and activity/levels of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-1, and IL-8. These findings also revealed the accumulation of cleaved caspase-3 and MG-H1 in macrophages around the centre of necrotic lesions in diabetes (48). In addition, heart disease and associated mortality in diabetes correlate with increased levels of the cyclooxygenase (COX)-1 isoform. Other causative factors include AGE activation, protein kinase C induction, and secondary reduction of nicotinamide adenine dinucleotide (NAD)+/NADPH (49,50). In addition, ROS elevation and AGE receptor activity increase the risk of cardiovascular complications in diabetic patients. A significant increase in COX-2 levels in the coronary vasculature of diabetic mice was reported in a preclinical study (51). These findings reveal the impact of hyperglycemia on the renal function of diabetic mice, as indicated by the interaction between prorenin receptor and renin/prorenin and eventual decline in the glomerular filtration rate.

1. **BIOMARKERS INDICATING CARDIOVASCULAR COMPLICATIONS IN DIABETES**

Several biomarkers can independently predict coronary heart disease in patients with type 2 diabetes. Significant biomarkers include galectin-3, cardiac troponins, soluble suppressor tumorigenicity-2, and natriuretic peptides in skeletal muscles, coronary arteries, kidneys, and myocardium. The American College of Cardiology (ACC) recommend the inclusion of biomarker analysis in the diagnostic workup to determine the risk of cardiovascular complications in patients with diabetes (type 2 and type 1) (52).

1. **DIAGNOSTIC WORKUP TO EVALUATE CARDIOVASCULAR COMPLICATIONS IN DIABETES**

Contemporary literature does not specify a standardized approach for evaluating dilated cardiomyopathy in diabetes. Accordingly, clinical correlation based on symptomatology and disease progression, predicted by imaging and biochemical assessments, strengthens medical decision-making. Doppler/echocardiographic imaging is the gold standard for evaluating diastolic dysfunction in patients with diabetes. Patients with early stage dilated cardiomyopathy may develop diastolic heart failure despite a normal ejection fraction. The literature reveals a 75% incidence rate of dilated cardiomyopathy in asymptomatic patients with diabetes (53,54). Left ventricular function in diabetes is affected by a range of factors, including calcium cycling, excitation-contraction coupling, left ventricular hypertrophy, and myocardial fibrosis. Magnetic resonance imaging (MRI) is a standard approach for evaluating the structure, function, and motility of the left ventricle in patients with diabetes. In addition, elevated HbA1C and high blood glucose levels are potential serological biomarkers for the development of diabetes (55,56). However, cellular damage/necrosis and the resultant cardiovascular complications are predicted by increased troponin levels. The onset and progression of fibrosis in diabetes is indicated by the abundance of MMP9. Cardiovascular disorders in diabetes are further determined by a clinically significant decline in metalloproteinase (TIMPs) tissue inhibitors, and the progression of dilated cardiomyopathy is predicted by marked elevations in O-linked beta-N-acetylglucosamine levels (57-60). Possible biomarkers for cardiac biochemical stress, cardiac myocyte necrosis, inflammation, fibrosis, myocardial hypertrophy, and extracellular matrix modelling in diabetes. Assessment of these pathogenic states is key to determining potential cardiovascular complications in patients with prediabetes or type 2 diabetes.

1. **THE THERAPEUTIC SIGNIFICANCE OF ROUTINE ORAL HYPOGLYCAEMIC AGENTS IN DIABETES**

Improvement in glycemic control is the key to minimizing cardiovascular complications in patients with diabetes. Evidence-based treatments focus on normalizing the blood glucose levels and decreasing the risk of clinical complications. The increased production of oral hypoglycemic drugs in recent decades has revolutionized the treatment landscape of type 2 diabetes by improving glycemic control and reducing the incidence of preventable complications. The dosages of hypoglycemic drugs were determined by the treatment goals based on symptomatology and clinical complications. The primary goal of these oral hypoglycaemics is to lower HbA1C levels below 7.0% to enhance glycemic control (61). They also activate pancreatic beta cells to improve insulin production and concomitantly reduce insulin resistance. Metformin is the first-line oral hypoglycaemic drug utilised to lower blood glucose levels. Other hypoglycaemics include GLP-1 agonists, DPP-4 inhibitors, sulfonylureas, and thiazolidinediones (62,63). However, potential complications associated with oral hypoglycemic drugs include hypoglycemia, increased appetite, tachycardia, confusion, irritability, shakiness, weight gain, and sweating. While sulfonylureas affect ischemic preconditions, pioglitazone increases the risk and incidence of heart failure. The utilization of gut hormones (incretin mimetics) also assists in lowering blood glucose levels based on improvements in the digestive processes (64,65). However, incretin administration increased the risk of diarrhoea, vomiting, nausea, and arrhythmia in non-responders. The recommended treatments for hyperglycemia in diabetes include sodium-glucose cotransporter 2 inhibitors, α-glucosidase inhibitors, peroxisome proliferator-activated receptor agonists, biguanides, and sulfonylureas. These drugs may be administered as monotherapy or in combination with other hypoglycemic agents. However, uncontrolled/persistent hypoglycemia lowers treatment efficacy, increases the risk of weight gain, and increases the incidence of metabolic complications. The potential challenges to the effective management of diabetes include long-term glycemic control and the lowering of treatment-emergent adverse events. Contemporary therapies aim to optimize glycemic goals and increase the quality-adjusted life-years of treated patients. The aim of quantifying the dosages of oral hypoglycemic monotherapies or combination therapies is to improve clinical outcomes and reduce adverse events. In addition, the choice of secondary therapy relies on the selection, characteristics, and outcomes of the primary treatment (65,66). Evidence-based guidelines recommend several drug combinations to improve treatment outcomes and reduce preventable adverse events in patients with diabetes. Commonly used combinations include 1) thiazolidinediones with glucosidase inhibitors and metformin, 2) metformin with repaglinide, 3) thiazolidinedione with sulfonylurea, 4) alpha-glucosidase inhibitors with sulfonylurea, and 5) metformin with sulfonylurea (67). The advantages of these combination therapies include synergistic efficacy at reduced dosages, low risk of refractory disease, and reduced incidence of toxicity.

1. **DIABETES MANAGEMENT VIA HERBAL REMEDIES**

Ongoing innovations in integrative medicine have increased the scope of using herbal remedies in routine treatment modalities for diabetes management. Herbal extracts derived from plants are used to treat diabetes complications owing to their medicinal properties (68). They are administered orally or via a topical route in accordance with treatment goals. Literature reveals the capacity of herbal medications to influence and modify the physiological processes of the human body. The pharmacological properties of their bioactive ingredients help to improve the body’s immunity and capacity to cope with type 2 diabetes. These ingredients are extracted from the flowers, fruits, roots, stems, and leaves. Countries, including India, China, and Tibet, continue to practice herbal remedies against various disease processes (69,70). The last decade has witnessed unprecedented advancements and transformations in herbal practices worldwide. Evidence suggests the capacity of herbal systems to prevent and control chronic disease conditions, including heart diseases, obesity, diabetes, asthma, hypertension, and autoimmune diseases. However, most advancements in herbal practices have been supported by anecdotal evidence. The scarcity of preclinical and clinical studies to support the medicinal value of various herbs and their bioactive compounds restricts their evidence-based utilization by the scientific community. As none of the currently practiced drugs/treatments provide a complete cure for diabetes and its fatal complications, future studies should investigate the diabetes management potential of herbal medicines. Studies should also examine the safety profiles and cost-effectiveness of herbal medicines in the context of type 2 diabetes. Human history reveals a wide range of benefits of traditional ailments, and ongoing studies should investigate their clinical outcomes in chronic conditions. The World Health Organization (WHO) has listed 21,000 plants based on their medicinal value and potential to manage the complications of a range of chronic diseases (71,72). Approximately 400 herbs have been identified by the WHO based on the therapeutic value of their bioactive compounds against diabetes; however, an insignificant percentage of these plants has been subjected to scientific investigation to determine their efficacy and safety outcomes. Approaches and trends concerning the use of herbal medicines against chronic conditions are rapidly changing, and people are more inclined towards benefiting from these alternative treatments based on their promising safety and efficacy based on anecdotal information. Few studies have demonstrated the possibility of preventing diabetes and its complications by including a range of phytochemical compounds in the diet. These phytochemicals include flavonoids, alkaloids, coumarins, lignans, stilbenes, terpenoids, and monoterpenes (73,74). Clinical trials have demonstrated the role of various plant species in increasing insulin secretion and minimizing insulin resistance by inducing extra pancreatic processes in diabetes. These species include *Syzygium cumini (Jamun), Pterocarpus marsupium (Malabar kino), Momordica charantia (bitter melon), Gymnema sylvestre (gurmar) leaves, Ficus bengalensis (banyan), Enicostemma littorale (Chhota chirayata), Coccinia indica, Cinnamomum tamala (Indian Bay Leaf), Clerodendron phlomoides (Aarni),* and *Allium cepa (Onion)* (75).

Phytochemicals in various plant species effectively regulate lipid and glucose metabolism by activating insulin signal transduction proteins, producing fatty acids, elevating glucose absorption in adipose and muscle tissues, and minimizing endogenous glucose production (76). Improved regulation of lipid and glucose metabolism improves the prevention and treatment of diabetes in high-risk patients. Findings from previous studies indicate the possible role of flavonoid-based foods in improving diabetes symptoms and complications (77). In addition, the regular consumption of these diets minimizes the risk and incidence of diabetes. Plant phytochemicals may prove to be novel therapies based on their promising role in controlling the onset of diabetes and its potential complications. Some commercially available antidiabetic products sourced from natural herbs include voglibose, miglitol, acarbose, and Pycnogenol (78). The bioactive ingredients of medicinal herbs improve glycemic control by reducing the activity of protein tyrosine phosphatase 1 B, alpha-amylase, and alpha-glucosidase. Several pharmaceutical companies are in the process of designing novel treatment molecules based on herbal extracts for diabetes management because of their low risk of adverse events. Herbal extracts can also minimize the incidence of secondary complications in patients with diabetes. Clinical studies continue to investigate the efficacy and safety of several herbal products to improve the prevention and management of diabetes and its deleterious manifestations (79).

1. **THE MEDICINAL PROPERTIES OF PHYTOCHEMICALS IN MANAGING DIABETES COMPLICATIONS**

The extraction of phytochemicals from medicinal herbs requires a range of complex procedures and mechanisms. Non-nutrient biomolecules incorporate phytochemicals, based on their capacity to prevent and manage a range of chronic diseases. However, these biomolecules are not routinely required by the human body to maintain a normal physiology (80). The potential antidiabetic properties of phytochemicals make them the most effective substances against type 2 diabetes and its associated clinical complications. The currently available herbal formulations for diabetes treatment/prevention include Syntax, Diabetes, Insulin, DiaCare, Chakrapani, Bitter Gourd Powder, and Pancreas Tonic-Glycoprin-180 CP. The contemporary literature provides strong scientific evidence supporting the diabetes prevention/treatment properties of plant-based phytochemicals. However, future studies should explore potential bioactive compounds for their integration into new treatment formulations against diabetes. It is important to examine drug-drug interactions between various phytochemical-based herbal formulations and identify their cytotoxic properties via rigorous clinical investigation. In addition, the mechanisms of action, pharmacokinetics, and pharmacodynamics of potential phytochemicals, including saponins, terpenoids, amino acids, glycosides, alkaloids, and polyphenols, are discussed. The molecules passing the final testing will be able to enhance metabolic processes and delay the fatal complications of diabetes in treated patients. Furthermore, clinical studies must compare the therapeutic outcomes, safety profiles, and synergism of these phytochemical-based herbal remedies with synthetic drugs to effectively transform the diabetes treatment landscape (81,82). Recent evidence has demonstrated the role of phytochemicals in altering biochemical pathways and activities of dipeptidyl peptidase-4, α-glucosidase, and α-amylase. In vivo and in vitro (preclinical) studies have revealed several other phytochemicals that require testing to determine their capacity for diabetes treatment/prevention in real-time scenarios (83).

1. **PREDOMINANT PHYTOCHEMICALS AGAINST DIABETES COMPLICATIONS**

Recent studies have investigated the efficacy and safety of flavonoids in a variety of chronic diseases, including diabetes, heart disease, neurological disorders, and cancers (**Figure 3**). The efficacy and safety of these flavonoids are based on their strong antioxidant properties; in addition to improving glucose homeostasis, they also strengthen the insulin sensitivity of skeletal muscles, adipose tissues, the liver, and the pancreas. Recent evidence has indicated the role of flavonoids in minimizing insulin resistance by enhancing endothelial function and improving vasodilation in blood vessels. They actively interact with vascular smooth muscle cells and increase their vasorelaxant capacity by inducing BKCa channels. Improved physiological regulation of intracellular calcium, membrane voltage, and neurotransmitter release eventually enhances endothelial function and glycemic control. Phytochemicals also disrupt potential alterations in endothelial function, which eventually delay the development of atherosclerotic lesions and associated cardiovascular complications in patients with diabetes (84,85).

**Figure 3: The therapeutic molecular targets of phytochemicals and the diseases they prevent [84-88].**

Contemporary literature reveals the possible role of phytochemicals in minimizing the accumulation of ROS and nitric oxide, which eventually results in vasodilation and reduction in systolic blood pressure in diabetes (86,87). Phytochemicals also facilitate the translocation of glucose transporter type 4 across the plasma membrane, which subsequently improves glucose absorption across adipose and skeletal muscles. Clinical studies have also demonstrated the role of flavonoids in improving hepatic function by controlling the function of genes responsible for gluconeogenesis. Reduced glucose synthesis in the liver eventually lowers serum blood glucose levels and increases glycaemic control (88). In addition, flavonoids improve the intestinal absorption of glucose by delaying the breakdown of complex carbohydrates. They also elevate insulin production, enhance cell vitality, and reduce oxidative stress in pancreatic β-cells. **Table 3** summarizes the therapeutic effects of flavonoids on retinopathy and cardiovascular complications in diabetic mice and in human epithelial/endothelial cell lines.

**Table 3: Therapeutic effects of flavonoids on retinopathy and cardiovascular complications in diabetic mice and human epithelial/endothelial cell lines.**

|  |
| --- |
| ***IN-VIVO* MODELS** |
| **Animal** | **DM** | **Model** | **Treatment** | **Results** | **Effect** |
| **DIABETIC RETINOPATHY COMPLICATIONS** |
| Rat | T1DM | STZ | Catechin 50–200 mg/kg/day 8 weeks | Modulation NF-κB pathway ↓ IL-1β, IL-6, and TNF-α | Anti-inflammatory |
| Rat | T1DM | STZ | Biochanin A 10–15 mg/kg/day. 6 weeks | ↓ TNFα, IL-1β, and VEGF | Anti-inflammatory and anti-angiogenic |
| Rat | T1DM | STZ | Trans-Resveratrol 5 mg/kg/day. 2–4 weeks | ↑ Cyp26b1 and Cyp3a9 transcription levels | Anti-oxidant |
| Rat | T1DM | STZ | Morus alba extract 100 mg/kg/day 16 weeks | ↓ Caspase-3, Bax and ↑ Bcl2; ↓TNF-α and IL-1β; ↑CAT, SOD, and GPx. ↓VEGF | Anti-apoptotic, anti-oxidant, anti-inflammatory and anti-angiogenic |
| Rat | T1DM | STZ | Naringenin 50 mg/kg/day 5 weeks | ↑GSH; ↓Caspase-3, Bax and ↑ Bcl2; ↓pro-BDNF and ↑BDNF | Neuroprotective, anti-oxidant and anti-apoptotic |
| Mouse | T1DM | STZ | Galangin 10 mg/kg/day 30 day | ↑Occludin and claudin1; ↓Iba-1 ↓ TNFα, IL-1β and IL-6 ↓p65, IκB and IKK phosphorylation | Neuroprotective and anti-inflammatory |
| Mouse | T2DM | db/db mouse | Chrysin 10 mg/kg/day 10 weeks | Increasing retinoid-binding proteins (RPE65, LRAT, RDH5, and rhodopsin) | Anti-oxidant |
| **CARDIOVASCULAR COMPLICATIONS** |
| Rat | T2DM | HGI | Rutin 25–50 mg/kg/day 12 weeks | ↓ inflammasome pathway in aortic tissue; ↓ROS generation | Anti-inflammatory and anti-oxidant |
| Rat | T2DM | HFD/STZ | Resveratrol 10 mg/kg/day 8 weeks | ↓ TLR4/MyD88/NF-κBsignaling pathway | Cardioprotective and anti-inflammatory |
| Rat | T1DM | STZ | Apigenin 100 mg/kg/day 7 months | ↓ cardiomyocyte enlargement; ↑SOD and GPx ↓ NF-κB/p65 signaling pathway activation ↓ Col-I, Col-III, CTGF, TGFβ | Cardioprotective, anti-oxidant, anti-inflammatory and anti-fibrotic |
| Rat | T1DM | STZ-IRIA | Resveratrol 5 mg/kg/day + Glibenclamide 5 mg/kg/day 6 weeks | ↑ Kir6.2 expression (subunit of KATP channel) | Anti-arrhythmic |
| Rat | T1DM | STZ | Heracleum Persicum 100 mg/kg/day; 8 weeks | ↓MDA; ↑GSH, CAT and SOD | Anti-oxidant |
| Rat | T1D | STZ | Isoquecertin 40 mg/kg/day 45 days | ↓ TG, PPL and FFA | Anti-hyperlipidaemic |
| Rat | T1D | STZ | Galangin 40 mg/kg 45 days | ↓ TG, PPL, total cholesterol, and FFA | Anti-hyperlipidaemic |
| Mouse | T2D | db/db mouse | Scutellarin 25–100 mg/kg 8 week | ↑ high-density lipoprotein cholesterol ↓ TG and cholesterol | Anti-hyperlipidaemic |
| **IN-VITRO MODELS** |
| **DIABETIC RETINOPATHY** |
| Human retinal pigment epithelial cell line | Glucose oxidase | Myricetin 40 µg/mL | Activation of Nrf2 ↑ SOD ↓ NOS2 | Anti-oxidant |
| **CARDIOVASCULAR COMPLICATIONS** |
| Human umbilical vein endothelial cells | HG | Rutin 30–100 µM | ↓Nox2 and Nox4 | Anti-oxidant |
| Human aortic endothelial cells | Palmitic acid | Resveratrol 50–100 µM | ↓ ROS production via AMPK-mTOR pathway | Autophagia and anti-oxidant |

1. **DIABETES TREATMENT POTENTIAL OF PHYTOCHEMICALS**
	1. **Rutin**

The flavonoid phytochemical ‘rutin (sophorin/quercetin-3-O-rutinoside)’is extracted from limes, lemons, apples, ginkgo, and St. John’s wort, buckwheat, eucalyptus, and citrus fruits. The primary role of rutin is to improve glycemic control by controlling ROS accumulation and minimizing pancreatic oxidative stress. It also enhances insulin secretion by preserving pancreatic beta cells and reducing gluconeogenesis. In addition, it minimized the absorption of glucose in the small intestine. Rutin effectively inhibits the accumulation of free radicals, which further reduces oxidative stress and minimizes life-threatening complications in diabetes. Rutin induces significant reductions in IL-6, sorbitol, and AGEs and alters the signalling cascades that eventually reduce the risk of clinical complications in diabetes (89). Intraperitoneal administration of 50-100 mg/kg rutin to mice with streptozotocin-induced type 1 diabetes led to improvements in fasting blood glucose and glycated hemoglobin levels (90). In addition, rutin activates hexosamine pathways, which eventually minimize gluconeogenesis and organ system complications in diabetes. In addition to controlling oxidative stress and reducing blood glucose concentration, rutin maintains the levels of albumin and blood urea nitrogen. It effectively activates anti-apoptotic molecules (including B-cell lymphoma 2) and reduces the concentration of caspase 3, which eventually minimizes cell death in various organ systems (91).

* 1. **Quercetin**

Quercetin dihydrate (3,3,4,5,7-pentahydroxyflavone or C15H14O9) or quercetin is a bioactive phytochemical known for its antimicrobial, antioxidant, anti-inflammatory, and anti-diabetic properties and is derived from red wine, green tea, berries, tea, onions, and apples. The structure of quercetin is similar to the configuration of other flavonoids, including luteolin, hesperidin, rutin, and naringenin. This phytochemical actively reduces glucose absorption in the intestine, and peripheral glucose utilization eventually improves glucose homeostasis, insulin resistance, and the pharmacological response. The outcomes from a recent systematic review and meta-analysis indicate the capacity of quercetin to minimize fasting glucose levels in laboratory animals within the dose range of 10 mg/kg, 25 mg/kg, and 50 mg/kg body weight (92). Quercetin also activates the adenosine monophosphate protein kinase pathway, which eventually induces glucose transporter type 4 translocation and alters adenosine diphosphate utilisation in mitochondria. The diabetes prevention and management properties of quercetin are indicated by its role in replenishing hepatic glycogen, gluconeogenesis, and phosphoinositide 3-kinase activation in streptozotocin-induced diabetic mice. Findings from a preclinical study reveal the outcomes of the two-week administration of quercetin in streptozotocin-induced diabetic mice; these outcomes include improved cell survival, enhanced serum insulin accumulation, low blood glucose levels, improved hepatic glucokinase activity, enhanced glucose tolerance, and reduced triglyceride/plasma cholesterol levels. Results from preclinical studies also indicate improvements in pancreatic beta cell structure/function, glucose metabolism, inflammatory processes, and oxidative state in streptozotocin-induced diabetic mice. Quercetin effectively modulates the activity of nuclear factor kappa B, which eventually improves insulin secretion and glycemic control (93-95).

* 1. **Hesperidin**

The saturated aglycone derivative ‘hesperidin’ is a bioflavonoid derived from sweet oranges, lemons, gooseberry, cranberry, and raspberry. Clinical studies have indicated the medicinal value of hesperidin in a range of conditions, including diabetes, inflammation, memory impairment, allergies, and neurological disorders. Its neuroprotective, antioxidant, and anti-inflammatory properties add value to its pharmacological profile against chronic diseases. Preclinical studies have indicated the role of hesperidin supplements in reducing blood glucose levels by regulating the function of glycolytic liver enzymes and controlling gluconeogenesis. It also induces lipolysis, reduces the activity of lipid-metabolizing hepatic enzymes, and enhances fecal excretion of triglycerides. Hesperidin upregulates peroxisome proliferator-activated receptors and glucose transporter type 4 translocation that eventually stabilises the blood glucose levels and improves glycaemic control. Evidence demonstrates the role of 10 g/kg hesperidin in reducing the accumulation of glucose-6 phosphate and glucose levels in streptozotocin-induced diabetic mice (96-101). In addition, it improves glycemic control by regulating lipolysis and carbohydrate metabolism. Findings from several preclinical studies also indicate the potential of hesperidin to reverse liver and kidney damage by upregulating the klotho and fibroblast growth factor 23 pathways in streptozotocin-induced diabetic mice (102).

* 1. **Resveratrol**

Stilbenoid ‘resveratrol’ is a natural food ingredient derived from plants across the globe based on its medicinal value. The pharmacological properties of resveratrol assist in the treatment of several diseases, including Alzheimer’s disease, diabetes, heart diseases, and cancer. The cardioprotective role of resveratrol is based on its potential to control systolic and diastolic blood pressure. In addition, resveratrol improves vascular function and muscle contractility by inhibiting the activity of rho-associated protein kinase, adenosine monophosphate-activated protein kinase (myosin light chain phosphorylation by angiotensin II), and myosin phosphatase target subunit 1 (103-105). The vasodilation property of resveratrol is due to its ability to block the diacylglycerol and inositol triphosphate signalling pathways. Resveratrol also suppresses triglyceride levels and the expression of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, thereby lowering serum cholesterol levels. In addition to its synergism with metformin, resveratrol reduces apoptosis and upregulates glucose transporter 4 translocation in diabetes (106,107).

* 1. **Other phytochemicals**

The isoquinoline alkaloid ‘berberine’ effectively reduces the risk of cognitive impairment, enhances insulin resistance, maintains total cholesterol, and reduces blood glucose levels. The flavonoid ‘naringenin’ is recognized in the scientific literature for its cardioprotective, antiadipogenic, anti-inflammatory, antibacterial, antiviral, antitumor, and antioxidant properties (108-110). Kaempferol, the predominant flavonoid aglycone, is known for its antidiabetic, neuroprotective, cardioprotective, antitumor, antioxidant, anti-inflammatory, and antimicrobial potential. The therapeutic implications of the natural phenol ‘chrysin’ are observed in neurodegenerative diseases, diabetes, and cancers (111,112). It also helps reduce inflammation and oxidative stress in diabetic complications. Similarly, scutellarin is a potential phytochemical with promising mechanisms of action against diabetes (vascular complications), Helicobacter pylori infection, Alzheimer’s disease, cerebral ischemia, and cardiovascular complications. Future studies should re-examine the treatment profile of these phytochemicals against retinopathy and cardiovascular diseases in diabetes (113,114).

**CONCLUSION**

The progressive clinical manifestations of diabetes reciprocate with inflammatory processes and increase in oxidative stress. Phytochemicals may prove to be promising therapeutic modalities against diabetes because of their antihyperglycemic, antioxidant, and anti-inflammatory properties. Their interaction and interference with cellular metabolites and pathological processes in the retina may challenge the onset and progression of diabetic retinopathy. Similarly, their cholesterol-lowering capacity may assist in reducing the incidence of hyperlipidaemia, thereby minimizing the risk of cardiovascular disease in diabetes. Therapeutic utilization of phytochemicals is currently limited owing to their low bioavailability and tissue assimilation capacity. Future studies should determine robust tools and techniques to enhance the bioavailability of phytochemicals and reevaluate their efficacy and safety in diabetes. It is also important to standardize the dosages of crude extracts of phytochemicals based on their medicinal value and diabetes management goals. Adjuvant therapies based on phytochemicals may revolutionize the therapeutic landscape of diabetes and transform its medical management/prevention and serious complications. Finally, the combination treatments based on routine drugs and phytochemicals may reduce the prevalence of diabetes manifestations and the incidence of safety events, and add to the quality-adjusted life years of the treated patients.

**References**

1. Benenson, I., Waldron, F.A. and Holly, C., 2023. A Systematic Review and Meta-analysis of the Clinical and Epidemiological Characteristics of Patients with Hypertensive Emergencies: Implication for Risk Stratification. High Blood Pressure & Cardiovascular Prevention, pp.1-13.
2. Wang, Z., Tang, J., Jin, E., Ren, C., Li, S., Zhang, L., Zhong, Y., Cao, Y., Wang, J., Zhou, W. and Zhao, M., 2023. Zongyi Wang1, Jiyang Tang1, Enzhong Jin1, Chi Ren1, Siying Li1, Linqi Zhang1, Yusheng Zhong1, Yu Cao1, Jianmin Wang2, Wei Zhou3, Mingwei Zhao1, Lvzhen Huang1 and Jinfeng Qu1. Ocular complications associated with diabetes mellitus, p.5908.
3. Rajiah, P.S., François, C.J. and Leiner, T., 2023. Cardiac MRI: state of the art. Radiology, 307(3), p.e223008.
4. Verma, A., Jha, A., Alagorie, A.R. and Sharma, R., 2023. Association of anthropometric parameters as a risk factor for development of diabetic retinopathy in patients with diabetes mellitus. Eye, 37(2), pp.303-308.
5. Yang, J. and Jiang, S., 2023. Development and validation of a model that predicts the risk of diabetic retinopathy in type 2 diabetes mellitus patients. Acta Diabetologica, 60(1), pp.43-51.
6. Verma, A., Jha, A., Alagorie, A.R. and Sharma, R., 2023. Association of anthropometric parameters as a risk factor for development of diabetic retinopathy in patients with diabetes mellitus. Eye, 37(2), pp.303-308.
7. Kropp, M., Golubnitschaja, O., Mazurakova, A., Koklesova, L., Sargheini, N., Vo, T.T.K.S., de Clerck, E., Polivka Jr, J., Potuznik, P., Polivka, J. and Stetkarova, I., 2023. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications—Risks and mitigation. EPMA Journal, 14(1), pp.21-42.
8. Rezazadeh-Gavgani, E., Oladghaffari, M., Bahramian, S., Majidazar, R. and Dolati, S., 2023. MicroRNA-21: A critical underestimated molecule in Diabetic Retinopathy. Gene, p.147212.
9. Zhou, J. and Chen, B., 2023. Retinal Cell Damage in Diabetic Retinopathy. Cells, 12(9), p.1342.
10. Bajka, A., Bacci, T., Wiest, M.R.J., Brinkmann, M., Hamann, T., Toro, M. and Zweifel, S.A., 2023. Feasibility and Clinical Utility of Wide-Field Optical Coherence Tomography Angiography Compared to Ultrawide-Field Fluorescein Angiography in Patients with Diabetic Retinopathy. Klinische Monatsblätter für Augenheilkunde, 240(04), pp.490-495.
11. Shariatzadeh, M., Binda, T.R., van Holten-Neelen, C., ten Berge, J.C., Martinez Ciriano, J.P., Wong, K.T., Dik, W.A. and Leenen, P.J., 2023. Aberration in myeloid-derived pro-angiogenic cells in type-2 diabetes mellitus; implication for diabetic retinopathy?. Frontiers in Ophthalmology, 3, p.1119050.
12. Tang, Y., Shi, Y. and Fan, Z., 2023. The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy. Frontiers in Endocrinology, 14, p.1102361.
13. Zgutka, K., Tkacz, M., Tomasiak, P. and Tarnowski, M., 2023. A Role for Advanced Glycation End Products in Molecular Ageing. International Journal of Molecular Sciences, 24(12), p.9881.
14. Tan, T.E. and Wong, T.Y., 2023. Diabetic retinopathy: Looking forward to 2030. Frontiers in Endocrinology, 13, p.1077669.
15. González, P., Lozano, P., Ros, G. and Solano, F., 2023. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. International Journal of Molecular Sciences, 24(11), p.9352.
16. Rodella, U., Honisch, C., Gatto, C., Ruzza, P. and D’Amato Tóthová, J., 2023. Antioxidant Nutraceutical Strategies in the Prevention of Oxidative Stress Related Eye Diseases. Nutrients, 15(10), p.2283.
17. McCann, M., Li, Y., Baccouche, B. and Kazlauskas, A., 2023. VEGF Induces Expression of Genes That Either Promote or Limit Relaxation of the Retinal Endothelial Barrier. International Journal of Molecular Sciences, 24(7), p.6402.
18. Pramotton, F.M., Abukar, A., Hudson, C., Dunbar, J., Potterton, A., Tonnicchia, S., Taddei, A., Mazza, E. and Giampietro, C., 2023. DYRK1B inhibition exerts senolytic effects on endothelial cells and rescues endothelial dysfunctions. Mechanisms of Ageing and Development, p.111836.
19. Chen, C., Ding, P., Yan, W., Wang, Z., Lan, Y., Yan, X., Li, T. and Han, J., 2023. Pharmacological roles of miRNAs in diabetic retinopathy with a focus on oxidative stress and inflammation. Biochemical Pharmacology, p.115643.
20. Wang, E., Feng, B. and Chakrabarti, S., 2023. MicroRNA 9 Is a Regulator of Endothelial to Mesenchymal Transition in Diabetic Retinopathy. Investigative Ophthalmology & Visual Science, 64(7), pp.13-13.
21. Anisimov, A., Fang, S., Hemanthakumar, K.A., Örd, T., van Avondt, K., Chevre, R., Toropainen, A., Singha, P., Gilani, H., Nguyen, S.D. and Karaman, S., 2023. The angiopoietin receptor Tie2 is atheroprotective in arterial endothelium. Nature Cardiovascular Research, 2(3), pp.307-321.
22. Dieter, C., Lemos, N.E., de Faria Corrêa, N.R., Assmann, T.S., Pellenz, F.M., Canani, L.H., Brondani, L.D.A., Bauer, A.C. and Crispim, D., 2023. Polymorphisms in TIE2 and ANGPT-1 genes are associated with protection against diabetic retinopathy in a Brazilian population. Archives of Endocrinology and Metabolism, 67, p.e000624.
23. García-Macedo, R. and de los Ángeles Fortis, M., 2023. The Immune System and Inflammation in Type 2 Diabetes. In The Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues (pp. 171-196). Cham: Springer International Publishing.
24. Georgiou, M. and Prokopiou, E., 2023. Diabetic retinopathy and the role of Omega-3 PUFAs: A narrative review. Experimental Eye Research, p.109494.
25. González, P., Lozano, P., Ros, G. and Solano, F., 2023. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. International Journal of Molecular Sciences, 24(11), p.9352.
26. Zhan, L., 2023. Frontiers in Understanding the Pathological Mechanism of Diabetic Retinopathy. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 29, pp.e939658-e939658.
27. Andrés-Blasco, I., Gallego-Martínez, A., Machado, X., Cruz-Espinosa, J., Di Lauro, S., Casaroli-Marano, R., Alegre-Ituarte, V., Arévalo, J.F. and Pinazo-Durán, M.D., 2023. Oxidative Stress, Inflammatory, Angiogenic, and Apoptotic molecules in Proliferative Diabetic Retinopathy and Diabetic Macular Edema Patients. International Journal of Molecular Sciences, 24(9), p.8227.
28. Chintala, S.B. and Ganta, S., 2023. Diabetic nephropathy: prevalence, pathogenesis and signalling pathways. Current Science (00113891), 124(8).
29. Zhang, Z., Huang, Q., Zhao, D., Lian, F., Li, X. and Qi, W., 2023. The impact of oxidative stress-induced mitochondrial dysfunction on diabetic microvascular complications. Frontiers in Endocrinology, 14, p.1112363.
30. González, P., Lozano, P., Ros, G. and Solano, F., 2023. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. International Journal of Molecular Sciences, 24(11), p.9352.
31. Lee, J., Kim, Y.J., Lee, J.Y., Yoon, Y.H. and Kim, J.G., 2023. Predictive factors for microvascular recovery after treatments for diabetic retinopathy. BMC ophthalmology, 23(1), pp.1-8.
32. Alzahrani, B.A., Salamatullah, H.K., Alsharm, F.S., Baljoon, J.M., Abukhodair, A.O., Ahmed, M.E., Malaikah, H. and Radi, S., 2023. The effect of different types of anemia on HbA1c levels in non-diabetics. BMC Endocrine Disorders, 23(1), p.24.
33. Akhetova, N., Abylaiuly, Z. and Bolshakova, S., 2023. The Importance of Fructosamine for Monitoring the Compensation and Effectiveness of Diabetes Treatment. Journal of Diabetes Science and Technology, p.19322968231174921.
34. ElSayed, N.A., Aleppo, G., Aroda, V.R., Bannuru, R.R., Brown, F.M., Bruemmer, D., Collins, B.S., Hilliard, M.E., Isaacs, D., Johnson, E.L. and Kahan, S., 2023. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023. Diabetes Care, 46(Supplement\_1), pp.S41-S48.
35. ElSayed, N.A., Aleppo, G., Aroda, V.R., Bannuru, R.R., Brown, F.M., Bruemmer, D., Collins, B.S., Cusi, K., Das, S.R., Gibbons, C.H. and Giurini, J.M., 2023. Summary of Revisions: Standards of Care in Diabetes—2023. Diabetes Care, 46(Supplement\_1), pp.S5-S9.
36. Babes, E.E., Bustea, C., Behl, T., Abdel-Daim, M.M., Nechifor, A.C., Stoicescu, M., Brisc, C.M., Moisi, M., Gitea, D., Iovanovici, D.C. and Bungau, A.F., 2022. Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy. Biomedicine & Pharmacotherapy, 148, p.112772.
37. Vesa, C.M., Popa, L., Popa, A.R., Rus, M., Zaha, A.A., Bungau, S., Tit, D.M., Corb Aron, R.A. and Zaha, D.C., 2020. Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors. Diagnostics, 10(5), p.314.
38. Fishbein, G.A., Fishbein, M.C., Wang, J. and Buja, L.M., 2022. Myocardial ischemia and its complications. In Cardiovascular pathology (pp. 407-445). Academic Press.
39. Letarte, L. and Bhimaraj, A., 2020. Chronic rejection. Contemporary Heart Transplantation, pp.421-448.
40. Li, A., Gao, M., Liu, B., Qin, Y., Chen, L., Liu, H., Wu, H. and Gong, G., 2022. Mitochondrial autophagy: Molecular mechanisms and implications for cardiovascular disease. Cell Death & Disease, 13(5), p.444.
41. Shires, S.E. and Gustafsson, Å.B., 2015. Mitophagy and heart failure. Journal of molecular medicine, 93, pp.253-262.
42. Morales, P.E., Arias-Durán, C., Ávalos-Guajardo, Y., Aedo, G., Verdejo, H.E., Parra, V. and Lavandero, S., 2020. Emerging role of mitophagy in cardiovascular physiology and pathology. Molecular aspects of medicine, 71, p.100822.
43. Tong, M. and Sadoshima, J., 2016. Mitochondrial autophagy in cardiomyopathy. Current opinion in genetics & development, 38, pp.8-15.
44. Zhang, R., Krigman, J., Luo, H., Ozgen, S., Yang, M. and Sun, N., 2020. Mitophagy in cardiovascular homeostasis. Mechanisms of ageing and development, 188, p.111245.
45. Filippatos, T.D., Alexakis, K., Mavrikaki, V. and Mikhailidis, D.P., 2022. Nonalcoholic fatty pancreas disease: Role in metabolic syndrome,“prediabetes,” diabetes and atherosclerosis. Digestive Diseases and Sciences, pp.1-16.
46. Yanai, H. and Yoshida, H., 2019. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. International journal of molecular sciences, 20(5), p.1190.
47. Mirabito Colafella, K.M., van Dorst, D.C., Neuman, R.I., Doorn, L.V., Neves, K.B., Montezano, A.C., Garrelds, I.M., van Veghel, R., de Vries, R., Uijl, E. and Clahsen-van Groningen, M.C., 2022. Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage. Clinical Science, 136(9), pp.675-694.
48. Imran, M., Rauf, A., Khalil, A.A., Bawazeer, S., Patel, S. and Shah, Z.A., 2021. Anti-inflammatory properties of bioactive compounds from medicinal plants. In Health Benefits of Secondary Phytocompounds from Plant and Marine Sources (pp. 81-108). Apple Academic Press.
49. Iqubal, A., Rahman, S.O., Ahmed, M., Bansal, P., Haider, M.R., Iqubal, M.K., Najmi, A.K., Pottoo, F.H. and Haque, S.E., 2021. current quest in natural bioactive compounds for Alzheimer’s disease: multi-targeted-designed-ligand based approach with preclinical and clinical based evidence. Current Drug Targets, 22(6), pp.685-720.
50. Koju, N., Qin, Z.H. and Sheng, R., 2022. Reduced nicotinamide adenine dinucleotide phosphate in redox balance and diseases: a friend or foe?. Acta Pharmacologica Sinica, 43(8), pp.1889-1904.
51. Wang, L., Cheng, C.K., Yi, M., Lui, K.O. and Huang, Y., 2022. Targeting endothelial dysfunction and inflammation. Journal of Molecular and Cellular Cardiology, 168, pp.58-67.
52. Lawton, J.S., Tamis-Holland, J.E., Bangalore, S., Bates, E.R., Beckie, T.M., Bischoff, J.M., Bittl, J.A., Cohen, M.G., DiMaio, J.M., Don, C.W. and Fremes, S.E., 2022. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(3), pp.e4-e17.
53. Horodinschi, R.N. and Diaconu, C.C., 2022. Heart Failure and Atrial Fibrillation: Diastolic Function Differences Depending on Left Ventricle Ejection Fraction. Diagnostics, 12(4), p.839.
54. Yang, Z., Liu, Y., Li, Z., Feng, S., Lin, S., Ge, Z., Fan, Y., Wang, Y., Wang, X. and Mao, J., 2023. Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies. Biomedicine & Pharmacotherapy, 164, p.115011.
55. Singh, T., Joshi, S., Kershaw, L.E., Dweck, M.R., Semple, S.I. and Newby, D.E., 2023. Manganese‐Enhanced Magnetic Resonance Imaging of the Heart. Journal of Magnetic Resonance Imaging, 57(4), pp.1011-1028.
56. Murtaza, G., Virk, H.U.H., Khalid, M., Lavie, C.J., Ventura, H., Mukherjee, D., Ramu, V., Bhogal, S., Kumar, G., Shanmugasundaram, M. and Paul, T.K., 2019. Diabetic cardiomyopathy-A comprehensive updated review. Progress in cardiovascular diseases, 62(4), pp.315-326.
57. Latosinska, A., Siwy, J., Faguer, S., Beige, J., Mischak, H. and Schanstra, J.P., 2021. Value of urine peptides in assessing kidney and cardiovascular disease. PROTEOMICS–Clinical Applications, 15(1), p.2000027.
58. Reiss, A.B., Ahmed, S., Johnson, M., Saeedullah, U. and De Leon, J., 2023. Exosomes in Cardiovascular Disease: From Mechanism to Therapeutic Target. Metabolites, 13(4), p.479.
59. Dozio, E., Massaccesi, L. and Corsi Romanelli, M.M., 2021. Glycation and Glycosylation in Cardiovascular Remodeling: Focus on Advanced Glycation End Products and O-Linked Glycosylations as Glucose-Related Pathogenetic Factors and Disease Markers. Journal of Clinical Medicine, 10(20), p.4792.
60. Reese-Petersen, A.L., Olesen, M.S., Karsdal, M.A., Svendsen, J.H. and Genovese, F., 2020. Atrial fibrillation and cardiac fibrosis: A review on the potential of extracellular matrix proteins as biomarkers. Matrix biology, 91, pp.188-203.
61. Brož, J., Janíčková Ždárská, D., Štěpánová, R. and Kvapil, M., 2019. Addition of basal insulin to oral antidiabetic agents in patients with inadequately controlled type 2 diabetes leads to improved HbA1c levels: metabolic control, frequency of hypoglycemia, and insulin titration analysis as results of a prospective observational study (Bali study). Diabetes Therapy, 10, pp.663-672.
62. Padhi, S., Nayak, A.K. and Behera, A., 2020. Type II diabetes mellitus: a review on recent drug-based therapeutics. Biomedicine & Pharmacotherapy, 131, p.110708.
63. Khan, M.K. and Baig, R.U., 2022. Pharmacotherapy of Diabetes Mellitus Type 2: A Review on Various Hypoglycemics. Journal of Clinical and Nursing Research, 6(5), pp.57-67.
64. Sivakumar, P.M., Prabhawathi, V., Zarrabi, A., Akthar, S. and Prabhakar, P.K., 2021. Current trends in the therapeutic strategies for diabetes management. Current Medicinal Chemistry, 28(23), pp.4616-4637.
65. Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J.G. and Lew, E., 2019. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Therapy, 10, pp.437-449.
66. Al-Adwi, M.E., Al-Haswsa, Z.M., Alhmmadi, K.M., Eissa, Y.A., Hamdan, A., Bawadi, H. and Tayyem, R.F., 2023. Effects of different diets on glycemic control among patients with type 2 diabetes: A literature review. Nutrition and health, 29(2), pp.215-221.
67. Ahmed, D., Sharma, M., Kumar, V. and Yadav, P.S., 2012. An emerging protagonist: Sodium Glucose Co-transporters (SGLTs) as a burgeoning target for the treatment of diabetes mellitus. Nature Precedings, pp.1-1.
68. Dirir, A.M., Daou, M., Yousef, A.F. and Yousef, L.F., 2022. A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes. Phytochemistry Reviews, 21(4), pp.1049-1079.
69. Bommakanti, V., Puthenparambil Ajikumar, A., Sivi, C.M., Prakash, G., Mundanat, A.S., Ahmad, F., Haque, S., Prieto, M.A. and Rana, S.S., 2023. An Overview of Herbal Nutraceuticals, Their Extraction, Formulation, Therapeutic Effects and Potential Toxicity. Separations, 10(3), p.177.
70. Babich, O., Sukhikh, S., Prosekov, A., Asyakina, L. and Ivanova, S., 2020. Medicinal plants to strengthen immunity during a pandemic. Pharmaceuticals, 13(10), p.313.
71. Kumar, S., Mittal, A., Babu, D. and Mittal, A., 2021. Herbal medicines for diabetes management and its secondary complications. Current diabetes reviews, 17(4), pp.437-456.
72. Faizan S, Roohi TF, Raju RM, Yuvaraj S, Kumar BP. A Century-Old One-Pot Multicomponent Biginelli Reaction Products Still Finds a Niche in Drug Discoveries: Synthesis, Mechanistic studies and Diverse Biological Activities of Dihydropyrimidine. Journal of Molecular Structure. 2023 Jun 16:136020.
73. Kawatra, A., Gupta, S., Dhankhar, R., Singh, P. and Gulati, P., 2023. Application of Phytochemicals in Therapeutic, Food, Flavor, and Cosmetic Industries. In Phytochemical Genomics: Plant Metabolomics and Medicinal Plant Genomics (pp. 85-108). Singapore: Springer Nature Singapore.
74. Mehdi S, Roohi TF, Suman P, Srikanth MS, Krishna KL. Review on Phytochemistry and Pharmacological Properties of Momordica dioica Roxb.: Special Emphasis on Cardioprotective Activity. In Ancient and Traditional Foods, Plants, Herbs and Spices used in Cardiovascular Health and Disease (pp. 313-329). CRC Press.
75. Zhao, C., Yang, C., Wai, S.T.C., Zhang, Y., P. Portillo, M., Paoli, P., Wu, Y., San Cheang, W., Liu, B., Carpéné, C. and Xiao, J., 2019. Regulation of glucose metabolism by bioactive phytochemicals for the management of type 2 diabetes mellitus. Critical Reviews in Food Science and Nutrition, 59(6), pp.830-847.
76. Ansari, P., Akther, S., Hannan, J.M.A., Seidel, V., Nujat, N.J. and Abdel-Wahab, Y.H., 2022. Pharmacologically active phytomolecules isolated from traditional antidiabetic plants and their therapeutic role for the management of diabetes mellitus. Molecules, 27(13), p.4278.
77. Arulselvan, P., Ghofar, H.A.A., Karthivashan, G., Halim, M.F.A., Ghafar, M.S.A. and Fakurazi, S., 2014. Antidiabetic therapeutics from natural source: A systematic review. Biomedicine & Preventive Nutrition, 4(4), pp.607-617.
78. Singab, A.N., Youssef, F.S. and Ashour, M.L., 2014. Medicinal plants with potential antidiabetic activity and their assessment. Med Aromat Plants, 3(151), pp.2167-0412.
79. Rahman, M.M., Dhar, P.S., Anika, F., Ahmed, L., Islam, M.R., Sultana, N.A., Cavalu, S., Pop, O. and Rauf, A., 2022. Exploring the plant-derived bioactive substances as antidiabetic agent: an extensive review. Biomedicine & Pharmacotherapy, 152, p.113217.
80. Nyakudya, T.T., Tshabalala, T., Dangarembizi, R., Erlwanger, K.H. and Ndhlala, A.R., 2020. The potential therapeutic value of medicinal plants in the management of metabolic disorders. Molecules, 25(11), p.2669.
81. Ansari, P., Akther, S., Hannan, J.M.A., Seidel, V., Nujat, N.J. and Abdel-Wahab, Y.H., 2022. Pharmacologically active phytomolecules isolated from traditional antidiabetic plants and their therapeutic role for the management of diabetes mellitus. Molecules, 27(13), p.4278.
82. Alkhatib, D.H., Jaleel, A., Tariq, M.N.M., Feehan, J., Apostolopoulos, V., Cheikh Ismail, L., Stojanovska, L. and Dhaheri, A.S.A., 2021. The role of bioactive compounds from dietary spices in the management of metabolic syndrome: An overview. Nutrients, 14(1), p.175.
83. Huneif, M.A., Alshehri, D.B., Alshaibari, K.S., Dammaj, M.Z., Mahnashi, M.H., Majid, S.U., Javed, M.A., Ahmad, S., Rashid, U. and Sadiq, A., 2022. Design, synthesis and bioevaluation of new vanillin hybrid as multitarget inhibitor of α-glucosidase, α-amylase, PTP-1B and DPP4 for the treatment of type-II diabetes. Biomedicine & Pharmacotherapy, 150, p.113038.
84. Shemarova, I., Nesterov, V., Emelyanova, L. and Korotkov, S., 2021. Mitochondrial mechanisms by which gasotransmitters (H2S, NO and CO) protect cardiovascular system against hypoxia. Frontiers in Bioscience-Scholar, 13(2), pp.105-130.
85. Saraswat N, Wal P, Pal RS, Wal A, Pal Y, Roohi TF. A Detailed Biological Approach on Hormonal Imbalance Causing Depression in Critical Periods (Postpartum, Postmenopausal and Perimenopausal Depression) in Adult Women. The Open Biology Journal. 2021 Oct 5;9(1).
86. Suvorava, T., Metry, S., Pick, S. and Kojda, G., 2022. Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure. Biochemical Pharmacology, p.115256.
87. Banez, M.J., Geluz, M.I., Chandra, A., Hamdan, T., Biswas, O.S., Bryan, N.S. and Von Schwarz, E.R., 2020. A systemic review on the antioxidant and anti-inflammatory effects of resveratrol, curcumin, and dietary nitric oxide supplementation on human cardiovascular health. Nutrition Research, 78, pp.11-26.
88. Rajendram R, Patel VB, Preedy VR, editors. Ancient and Traditional Foods, Plants, Herbs and Spices used in Cardiovascular Health and Disease. CRC Press; 2023 Jul 31.
89. Muvhulawa, N., Dludla, P.V., Ziqubu, K., Mthembu, S.X., Mthiyane, F., Nkambule, B.B. and Mazibuko-Mbeje, S.E., 2022. Rutin ameliorates inflammation and improves metabolic function: A comprehensive analysis of scientific literature. Pharmacological Research, p.106163.
90. Mirahmad, M., Mohseni, S., Tabatabaei-Malazy, O., Esmaeili, F., Alatab, S., Bahramsoltani, R., Ejtahed, H.S., Qulami, H., Bitarafan, Z., Arjmand, B. and Nazeri, E., 2022. Antioxidative hypoglycemic herbal medicines with in vivo and in vitro activity against C-reactive protein; a systematic review. Phytomedicine, p.154615.
91. Şimşek, H., Akaras, N., Cihan, G.Ü.R., Küçükler, S. and Kandemir, F.M., 2023. Beneficial effects of Chrysin on Cadmium‐induced nephrotoxicity in rats: Modulating the levels of Nrf2/HO‐1, RAGE/NLRP3, and Caspase-3/Bax/Bcl-2 signaling pathways. Gene, p.147502.
92. Wal A, Wal P, Roohi TF. Role of Berries and Its Bioactive Compounds in Treating Hypertension: A Review. Current Aspects in Pharmaceutical Research and Development Vol. 1. 2021 Aug 18:10-29.
93. Roohi TF. Review on the miracle role of chia seeds (Salvia hispanica L.) nutritional and bioactive compounds in the treatment of cardiovascular disorder. J. Biomed. Pharm. Res. 2020; 9:42-9.
94. Wal A, Wal P, Roohi TF. A Review on Role of Berries and Its Bioactive Compounds in Treating Hypertension. hypertension. 2020; 9:10.
95. Yadav, E., Yadav, P., Khan, M.M.U., Singh, H. and Verma, A., 2022. Resveratrol: A potential therapeutic natural polyphenol for neurodegenerative diseases associated with mitochondrial dysfunction. Frontiers in Pharmacology, p.3811.
96. Pal RS, Saraswat N, Wal P, Wal A, Pal Y, Roohi TF. An Insight on the Association of Psychological Studies, Cognitive Sciences and Meditation in Treating Depression. Current Psychopharmacology. 2019 Dec 1;8(3):177-93.
97. Madureira, M.B., Concato, V.M., Cruz, E.M.S., Bitencourt de Morais, J.M., Inoue, F.S.R., Concimo Santos, N., Gonçalves, M.D., Cremer de Souza, M., Basso Scandolara, T., Fontana Mezoni, M. and Galvani, M., 2023. Naringenin and Hesperidin as Promising Alternatives for Prevention and Co-Adjuvant Therapy for Breast Cancer. Antioxidants, 12(3), p.586.
98. Han, R., Li, J., Shin, H.D., Chen, R.R., Du, G., Liu, L. and Chen, J., 2014. Recent advances in discovery, heterologous expression, and molecular engineering of cyclodextrin glycosyltransferase for versatile applications. Biotechnology Advances, 32(2), pp.415-428.
99. Roohi TF, Wal A. Phytochemical evaluation and standardization of polyherbal ethyl acetate extract and its gel-based formulation obtained from berries and flaxseed (EAPEG-BF). September 2021. [International Journal of Pharmaceutical Sciences and Research](https://www.researchgate.net/journal/International-Journal-of-Pharmaceutical-Sciences-and-Research-0975-8232) 12(9):5010-5017.
100. Allam, M.A., Khowailed, A.A., Elattar, S. and Mahmoud, A.M., 2022. Umbelliferone ameliorates oxidative stress and testicular injury, improves steroidogenesis and upregulates peroxisome proliferator-activated receptor gamma in type 2 diabetic rats. Journal of Pharmacy and Pharmacology, 74(4), pp.573-584.
101. Mehdi S, Roohi TF, Suman P, Srikanth MS, Krishna KL. Review on Phytochemistry and Pharmacological Properties of Momordica dioica Roxb.: Special Emphasis on Cardioprotective Activity. In Ancient and Traditional Foods, Plants, Herbs and Spices used in Cardiovascular Health and Disease (pp. 313-329). CRC Press.
102. Liu, S., Liu, K., Wang, Y., Wu, C., Xiao, Y., Liu, S., Yu, J., Ma, Z., Liang, H., Li, X. and Li, Y., 2023. Hesperidin methyl chalcone ameliorates lipid metabolic disorders by activating lipase activity and increasing energy metabolism. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1869(2), p.166620.
103. Zeng, Z., Wang, X., Cui, L., Wang, H., Guo, J. and Chen, Y., 2023. Natural Products for the Treatment of Pulmonary Hypertension: Mechanism, Progress, and Future Opportunities. Current Issues in Molecular Biology, 45(3), pp.2351-2371.
104. Cui, L., Yuan, T., Zeng, Z., Liu, D., Liu, C., Guo, J. and Chen, Y., 2022. Mechanistic and therapeutic perspectives of baicalin and baicalein on pulmonary hypertension: A comprehensive review. Biomedicine & Pharmacotherapy, 151, p.113191.
105. Varghese, R., Doss, C.G.P., Kumar, R.S., Almansour, A.I., Arumugam, N., Efferth, T. and Ramamoorthy, S., 2022. Cardioprotective effects of phytopigments via multiple signaling pathways. Phytomedicine, 95, p.153859.
106. Qiu, Y., Shi, Y.N., Zhu, N., Zhang, S., Zhang, C.J., Gu, J., He, P., Dai, A.G. and Qin, L., 2023. A Lipid Perspective on Regulated Pyroptosis. International Journal of Biological Sciences, 19(8), p.2333.
107. Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y. and Assi, H.I., 2022. Metabolic syndrome: Updates on pathophysiology and management in 2021. International Journal of Molecular Sciences, 23(2), p.786.
108. Chen, N., Wang, X.C., Fan, L.L., Zhu, Y.H., Wang, Q. and Chen, Y.B., 2022. Berberine ameliorates lipopolysaccharide-induced cognitive impairment through SIRT1/NRF2/NF-κB signaling pathway in C57BL/6J Mice. Rejuvenation Research, 25(5), pp.233-242.
109. Mushtaq, Z., Imran, M., Saeed, F., Imran, A., Ali, S.W., Shahbaz, M., Alsagaby, S.A., Guerrero Sánchez, Y., Umar, M., Hussain, M. and Al Abdimonem, W., 2023. Berberine: a comprehensive Approach to combat human maladies. International Journal of Food Properties, 26(1), pp.787-807.
110. Palai, S., 2022. Berberine. In Nutraceuticals and health care (pp. 359-368). Academic Press.
111. Sivakumar, P.M., Prabhakar, P.K., Cetinel, S. and Prabhawathi, V., 2022. Molecular Insights on the Therapeutic Effect of Selected Flavonoids on Diabetic Neuropathy. Mini Reviews in Medicinal Chemistry, 22(14), pp.1828-1846.
112. Fatima, M.T., Bhat, A.A., Nisar, S., Fakhro, K.A. and Akil, A.S.A.S., 2022. The role of dietary antioxidants in type 2 diabetes and neurodegenerative disorders: An assessment of the benefit profile. Heliyon, p.e12698.
113. Alugoju, P., Krishna Swamy, V.K.D., Anthikapalli, N.V.A. and Tencomnao, T., 2022. Health benefits of astaxanthin against age-related diseases of multiple organs: A comprehensive review. Critical Reviews in Food Science and Nutrition, pp.1-66.
114. Mahmud, A.R., Ema, T.I., Siddiquee, M., Shahriar, A., Ahmed, H., Mosfeq-Ul-Hasan, M., Rahman, N., Islam, R., Uddin, M.R. and Mizan, M.F.R., 2023. Natural flavonols: actions, mechanisms, and potential therapeutic utility for various diseases. Beni-Suef University Journal of Basic and Applied Sciences, 12(1), pp.1-18.

**ACKNOWLEDGEMENT**

I would like to express my sincere gratitude to my supervisor **Dr. K L Krishna** for providing me with invaluable guidance and support throughout the preparation of this chapter. Their extensive knowledge, constructive feedback, and insightful discussions have been helpful in shaping the direction and quality of the chapter work. Their mentorship has been an invaluable asset to our academic pursuits and we are fortunate to have had the opportunity to work under their supervision. I would like to thank **Dr. Seema Mehdi** and **Syed Faizan** for their support and assistance in reviewing and writing the manuscript. The authors are indebted to all those who have supported in bringing the present shape to the chapter successfully and hope that it will provide comprehensive information on the subject for undergraduate, postgraduate, and researchers, and will benefit readers in general.

**ABBREVIATIONS**

**AGEs:** advanced glycation end products

**CRM:** corneal confocal microscopy

**DNA:** deoxyribonucleic acid

**eGFR:** estimated glomerular filtration rate

**ERG:** Electroretinogram

**NO:** nitric oxide

**PAI-1:** plasminogen activator inhibitor 1

**PEDF:** pigment epithelium-derived factor

**RAGE:** receptor for advanced glycation end products

**SAF:** Skin autofluorescence

**SNPs:** single-nucleotide polymorphisms

**VEGF:** vascular endothelial growth factor

**IRMA:** intraretinal microvascular abnormality

**NVD:** neovascularization on the disc

**BIOGRAPHICAL SKETCHES**

1. **Tamsheel Fatima Roohi**

Ph.D. Research Scholar, Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, Karnataka, India-570015.

1. **Syed Faizan**

Senior Research Fellow at the Indian Council of Medical Research, Ph.D. Research Scholar, Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Mysuru, JSS Academy of Higher Education and Research (JSS AHER), Mysuru Karnataka, India-570015.

1. **Dr. K. L. Krishna**

Associate Professor & HOD, Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, Karnataka, India-570015.

1. **Dr. Seema Mehdi**

Lecturer, Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSS AHER), Mysuru, Karnataka, India-570015.